Compare DTI & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DTI | ADAG |
|---|---|---|
| Founded | 1984 | 2011 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 76.7M | 84.8M |
| IPO Year | N/A | 2021 |
| Metric | DTI | ADAG |
|---|---|---|
| Price | $2.83 | $1.88 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 113.5K | 61.0K |
| Earning Date | 11-06-2025 | 08-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $160,964,000.00 | $103,204.00 |
| Revenue This Year | $3.41 | $6,983.06 |
| Revenue Next Year | $1.30 | $36.05 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.46 | N/A |
| 52 Week Low | $1.43 | $1.30 |
| 52 Week High | $3.82 | $3.16 |
| Indicator | DTI | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 55.94 | 49.37 |
| Support Level | $2.70 | $1.76 |
| Resistance Level | $2.95 | $1.93 |
| Average True Range (ATR) | 0.25 | 0.14 |
| MACD | -0.01 | -0.00 |
| Stochastic Oscillator | 53.95 | 53.19 |
Drilling Tools International Corp manufactures, rents, inspects, and refurbishes downhole drilling tools primarily to companies in the oil and natural gas industry for bottom hole assemblies used in onshore and offshore horizontal and directional drilling. The company's United States operations have locations in Texas, California, Louisiana, Oklahoma, Pennsylvania, North Dakota, New Mexico, Utah, and Wyoming. The company's single segment derives revenues from customers by providing oilfield equipment and services to operators in the oil and natural gas sectors.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.